ID: ALA1631214

Max Phase: Preclinical

Molecular Formula: C18H23N3O2S

Molecular Weight: 345.47

Molecule Type: Small molecule

Representations

Canonical SMILES:  CC1CCCCC1NC(=O)COc1ncnc2sc3c(c12)CCC3

Standard InChI:  InChI=1S/C18H23N3O2S/c1-11-5-2-3-7-13(11)21-15(22)9-23-17-16-12-6-4-8-14(12)24-18(16)20-10-19-17/h10-11,13H,2-9H2,1H3,(H,21,22)

Standard InChI Key:  VEOCSWCVKDPCCM-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 345.47

Molecular Weight (Monoisotopic): 345.1511

AlogP: 3.25

#Rotatable Bonds: 4

Polar Surface Area: 64.11

Molecular Species: NEUTRAL

HBA: 5

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 5

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 1.41

CX LogP: 3.93

CX LogD: 3.93

Aromatic Rings: 2

Heavy Atoms: 24

QED Weighted: 0.92

Np Likeness Score: -2.08

References

1. Hosokawa-Muto J, Kamatari YO, Nakamura HK, Kuwata K..  (2009)  Variety of antiprion compounds discovered through an in silico screen based on cellular-form prion protein structure: Correlation between antiprion activity and binding affinity.,  53  (2): [PMID:19015328] [10.1128/aac.01112-08]

2. Pagadala NS, Bjorndahl TC, Joyce M, Wishart DS, Syed K, Landi A..  (2017)  The compound (3-{5-[(2,5-dimethoxyphenyl)amino]-1,3,4-thiadiazolidin-2-yl}-5,8-methoxy-2H-chromen-2-one) inhibits the prion protein conversion from PrPC to PrPSc with lower IC50 in ScN2a cells.,  25  (20): [PMID:28951092] [10.1016/j.bmc.2017.09.024]

Source

Source(1):

• Scientific Literature